Tag: Section 505A

Pediatric Exclusivity: How the FDA Extends Market Protection Without Changing Patents

Pediatric exclusivity gives drugmakers six extra months of market protection after completing FDA-requested studies in children. It doesn't extend patents-but it blocks generics from entering the market, even after patents expire.

Read More